Business
A New Paradigm in Tobacco and Nicotine Addiction: NFL Biosciences Demonstrates the Mechanism of Action of NFL-102 in a Video
MONTPELLIER, France, April 07, 2026--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announced today the release of a video illustrating the mechanism of action of NFL-102, a drug candidate that could transform the treatment of tobacco and nicotine addiction. Whereas current approaches are essentially limited to managing withdrawal symptoms via nicotinic receptors, N
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"A breakthrough mechanism of action targeting neural plasticity associated with addiction, particularly through the CREB regulator, a key factor in relapse","length":154,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":154,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"An educational video illustrating this new approach and making it easier to understand","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":86,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Upcoming conference presentations and a scientific publication","length":62,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":62,"olType":false},{"type":"text","content":"MONTPELLIER, France, April 07, 2026--(BUSINESS WIRE)--Regulatory News:","length":70,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announced today the release of a video illustrating the mechanism of action of NFL-102, a drug candidate that could transform the treatment of tobacco and nicotine addiction. Whereas current approaches are essentially limited to managing withdrawal symptoms via nicotinic receptors, NFL-102 acts directly on the deep neural mechanisms of addiction. It modulates the CREB regulator, which is involved in brain plasticity and relapse.","length":594,"tagName":"p"},{"type":"text","content":"https://www.youtube.com/watch?v=_4G8PDChbmA&feature=youtu.be","length":64,"tagName":"p"},{"type":"text","content":"This initiative builds on the company’s recent work, which has identified a novel mechanism of action targeting the underlying biological processes involved in nicotine addiction. With this presentation, NFL Biosciences aims to illustrate this new paradigm in an accessible way and to reaffirm its strategy of capitalizing on this differentiating mechanism in the clinical development of its drug candidate, NFL-102.","length":416,"tagName":"p"},{"type":"text","content":"Unlike current smoking cessation treatments, which primarily act on nicotinic receptors to reduce withdrawal symptoms, NFL-102 acts downstream of these receptors by modulating key signaling pathways inv...